Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Allogene Therapeutics (ALLO) Depreciation & Amortization (CF) (2019 - 2025)

Allogene Therapeutics' Depreciation & Amortization (CF) history spans 7 years, with the latest figure at $3.1 million for Q3 2025.

  • For Q3 2025, Depreciation & Amortization (CF) fell 3.43% year-over-year to $3.1 million; the TTM value through Sep 2025 reached $12.5 million, down 9.72%, while the annual FY2024 figure was $13.6 million, 3.95% down from the prior year.
  • Depreciation & Amortization (CF) for Q3 2025 was $3.1 million at Allogene Therapeutics, roughly flat from $3.1 million in the prior quarter.
  • Across five years, Depreciation & Amortization (CF) topped out at $4.2 million in Q4 2021 and bottomed at $1.9 million in Q1 2021.
  • The 5-year median for Depreciation & Amortization (CF) is $3.5 million (2023), against an average of $3.3 million.
  • The largest annual shift saw Depreciation & Amortization (CF) soared 130.04% in 2021 before it decreased 27.68% in 2022.
  • A 5-year view of Depreciation & Amortization (CF) shows it stood at $4.2 million in 2021, then fell by 27.68% to $3.1 million in 2022, then rose by 13.36% to $3.5 million in 2023, then decreased by 7.04% to $3.2 million in 2024, then dropped by 4.21% to $3.1 million in 2025.
  • Per Business Quant, the three most recent readings for ALLO's Depreciation & Amortization (CF) are $3.1 million (Q3 2025), $3.1 million (Q2 2025), and $3.1 million (Q1 2025).